Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition.


Journal

Cancer immunology research
ISSN: 2326-6074
Titre abrégé: Cancer Immunol Res
Pays: United States
ID NLM: 101614637

Informations de publication

Date de publication:
03 08 2022
Historique:
received: 12 10 2021
revised: 12 01 2022
accepted: 08 06 2022
pubmed: 17 6 2022
medline: 5 8 2022
entrez: 16 6 2022
Statut: ppublish

Résumé

Melanoma-derived brain metastases (MBM) represent an unmet clinical need because central nervous system progression is frequently an end stage of the disease. Immune checkpoint inhibitors (ICI) provide a clinical opportunity against MBM; however, the MBM tumor microenvironment (TME) has not been fully elucidated in the context of ICI. To dissect unique elements of the MBM TME and correlates of MBM response to ICI, we collected 32 fresh MBM and performed single-cell RNA sequencing of the MBM TME and T-cell receptor clonotyping on T cells from MBM and matched blood and extracranial lesions. We observed myeloid phenotypic heterogeneity in the MBM TME, most notably multiple distinct neutrophil states, including an IL8-expressing population that correlated with malignant cell epithelial-to-mesenchymal transition. In addition, we observed significant relationships between intracranial T-cell phenotypes and the distribution of T-cell clonotypes intracranially and peripherally. We found that the phenotype, clonotype, and overall number of MBM-infiltrating T cells were associated with response to ICI, suggesting that ICI-responsive MBMs interact with peripheral blood in a manner similar to extracranial lesions. These data identify unique features of the MBM TME that may represent potential targets to improve clinical outcomes for patients with MBM.

Identifiants

pubmed: 35706413
pii: 704915
doi: 10.1158/2326-6066.CIR-21-0870
pmc: PMC10201927
mid: NIHMS1818207
doi:

Substances chimiques

Immune Checkpoint Inhibitors 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

996-1012

Subventions

Organisme : NCI NIH HHS
ID : R37 CA258829
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA263381
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA227156
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA244975
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA221703
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA224070
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA220253
Pays : United States
Organisme : NCI NIH HHS
ID : K08 CA248960
Pays : United States

Informations de copyright

©2022 American Association for Cancer Research.

Références

Cancer Discov. 2017 Oct;7(10):1088-1097
pubmed: 28733428
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Nat Rev Immunol. 2019 Apr;19(4):255-265
pubmed: 30816340
J Neuroinflammation. 2020 Sep 17;17(1):273
pubmed: 32943056
Oncologist. 2021 Mar;26(3):231-241
pubmed: 33103803
Cell. 2020 Jun 25;181(7):1626-1642.e20
pubmed: 32470397
Clin Cancer Res. 2021 May 1;27(9):2383-2393
pubmed: 33376096
N Engl J Med. 2018 Aug 23;379(8):722-730
pubmed: 30134131
Nat Protoc. 2014 Jan;9(1):171-81
pubmed: 24385147
J Neurooncol. 2016 Oct;130(1):19-29
pubmed: 27436101
Trends Immunol. 2015 Oct;36(10):569-577
pubmed: 26431936
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Nature. 2021 Aug;596(7870):126-132
pubmed: 34290408
Cancer Discov. 2015 Nov;5(11):1164-1177
pubmed: 26410082
Cell. 2018 Nov 1;175(4):998-1013.e20
pubmed: 30388456
Nat Med. 2019 Aug;25(8):1251-1259
pubmed: 31359002
Nat Rev Immunol. 2020 Jan;20(1):25-39
pubmed: 31570880
Front Mol Neurosci. 2019 Nov 21;12:282
pubmed: 31824260
Nat Immunol. 2019 Mar;20(3):326-336
pubmed: 30778252
Nat Methods. 2016 Apr;13(4):329-332
pubmed: 26950746
Cell. 2015 Mar 12;160(6):1061-71
pubmed: 25728668
Nat Med. 2020 May;26(5):693-698
pubmed: 32405063
Immunity. 2019 Jan 15;50(1):253-271.e6
pubmed: 30471926
Cell Mol Immunol. 2005 Feb;2(1):1-10
pubmed: 16212905
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Cell. 2018 Nov 1;175(4):984-997.e24
pubmed: 30388455
Bioinformatics. 2011 Jun 15;27(12):1739-40
pubmed: 21546393
Nat Cancer. 2020 Feb;1(2):210-221
pubmed: 32110781
Cell. 2019 Feb 7;176(4):775-789.e18
pubmed: 30595452
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Nat Commun. 2020 Oct 8;11(1):5084
pubmed: 33033253
Nat Methods. 2020 Aug;17(8):793-798
pubmed: 32719530
Nat Med. 2015 Aug;21(8):938-945
pubmed: 26193342
J Exp Med. 2021 Apr 5;218(4):
pubmed: 33651881
Nat Rev Immunol. 2008 Mar;8(3):231-8
pubmed: 18301425
Cell. 2016 Mar 24;165(1):35-44
pubmed: 26997480
Front Immunol. 2021 Mar 25;12:633796
pubmed: 33841415
Nature. 2019 Nov;575(7783):512-518
pubmed: 31597160
Nucleic Acids Res. 2020 Jan 8;48(D1):D1057-D1062
pubmed: 31588507
Cancer Discov. 2019 May;9(5):628-645
pubmed: 30787016
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
Nat Rev Immunol. 2018 Feb;18(2):134-147
pubmed: 28990587
BMC Bioinformatics. 2011 Aug 04;12:323
pubmed: 21816040
Nat Rev Cancer. 2020 Jan;20(1):26-41
pubmed: 31601988
Cell. 2020 Jun 25;181(7):1643-1660.e17
pubmed: 32470396
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
Oncoimmunology. 2015 Jun 9;5(1):e1057388
pubmed: 26942067
Nat Commun. 2021 Oct 12;12(1):5955
pubmed: 34642316
Nature. 2015 Jul 16;523(7560):337-41
pubmed: 26030524
EClinicalMedicine. 2021 Sep 16;41:101134
pubmed: 34585125
Nat Med. 2018 Jul;24(7):994-1004
pubmed: 29892065
Cancer Cell. 2009 Sep 8;16(3):183-94
pubmed: 19732719
Nat Rev Cancer. 2020 Apr;20(4):218-232
pubmed: 32024970
J Exp Med. 2021 Apr 5;218(4):
pubmed: 33651880
Annu Rev Immunol. 2016 May 20;34:479-510
pubmed: 26927205
Science. 2015 Apr 3;348(6230):74-80
pubmed: 25838376
Cell. 2021 Mar 4;184(5):1281-1298.e26
pubmed: 33592174
Nat Immunol. 2018 Feb;19(2):108-119
pubmed: 29348500
Nat Med. 2020 May;26(5):688-692
pubmed: 32405062
Science. 2016 Apr 8;352(6282):189-96
pubmed: 27124452
Nature. 2020 Mar;579(7798):274-278
pubmed: 32103181
Nat Commun. 2021 Feb 1;12(1):729
pubmed: 33526794
Cell. 2020 Aug 20;182(4):886-900.e17
pubmed: 32783918
AAPS J. 2021 Mar 7;23(2):39
pubmed: 33677681
Immunity. 2016 Jun 21;44(6):1255-69
pubmed: 27332730

Auteurs

Christopher Alvarez-Breckenridge (C)

Departments of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts.

Samuel C Markson (SC)

Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, Massachusetts.
Evergrande Center for Immunological Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts.
Broad Institute, Harvard University and Massachusetts Institute of Technology, Cambridge, Massachusetts.
Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.

Jackson H Stocking (JH)

Department of Medicine, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts.

Naema Nayyar (N)

Department of Medicine, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts.

Matt Lastrapes (M)

Broad Institute, Harvard University and Massachusetts Institute of Technology, Cambridge, Massachusetts.
Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.
Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Matthew R Strickland (MR)

Department of Medicine, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts.
Massachusetts General Hospital Cancer Center, Boston, Massachusetts.

Albert E Kim (AE)

Department of Medicine, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts.
Massachusetts General Hospital Cancer Center, Boston, Massachusetts.

Magali de Sauvage (M)

Department of Medicine, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts.

Ashish Dahal (A)

Department of Medicine, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts.

Juliana M Larson (JM)

Department of Medicine, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts.

Joana L Mora (JL)

Broad Institute, Harvard University and Massachusetts Institute of Technology, Cambridge, Massachusetts.
Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.
Massachusetts General Hospital Cancer Center, Boston, Massachusetts.

Andrew W Navia (AW)

Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Institute for Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Ragon Institute, Harvard University, Massachusetts Institute of Technology, and Massachusetts General Hospital, Cambridge, Massachusetts.

Robert H Klein (RH)

Department of Medicine, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts.

Benjamin M Kuter (BM)

Department of Medicine, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts.

Corey M Gill (CM)

Department of Medicine, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts.

Mia Bertalan (M)

Department of Medicine, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts.

Brian Shaw (B)

Department of Medicine, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts.

Alexander Kaplan (A)

Department of Medicine, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts.

Megha Subramanian (M)

Department of Medicine, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts.

Aarushi Jain (A)

Department of Medicine, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts.

Swaminathan Kumar (S)

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Husain Danish (H)

Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York.
Weill Cornell Medical Center, New York, New York.

Michael White (M)

Department of Medicine, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts.

Osmaan Shahid (O)

Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.

Kristen E Pauken (KE)

Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, Massachusetts.
Evergrande Center for Immunological Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts.

Brian C Miller (BC)

Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, Massachusetts.
Evergrande Center for Immunological Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts.
Broad Institute, Harvard University and Massachusetts Institute of Technology, Cambridge, Massachusetts.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Dennie T Frederick (DT)

Division of Surgical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

Christine Hebert (C)

Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.

McKenzie Shaw (M)

Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.

Maria Martinez-Lage (M)

Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.

Matthew Frosch (M)

C. S. Kubik Laboratory for Neuropathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.

Nancy Wang (N)

Department of Medicine, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts.

Elizabeth Gerstner (E)

Massachusetts General Hospital Cancer Center, Boston, Massachusetts.

Brian V Nahed (BV)

Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts.

William T Curry (WT)

Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts.

Bob Carter (B)

Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts.

Daniel P Cahill (DP)

Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts.

Genevieve Marie Boland (GM)

Division of Surgical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

Benjamin Izar (B)

Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, New York.
Columbia Center for Translational Immunology, New York, New York.

Michael A Davies (MA)

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Arlene H Sharpe (AH)

Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, Massachusetts.
Evergrande Center for Immunological Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts.
Broad Institute, Harvard University and Massachusetts Institute of Technology, Cambridge, Massachusetts.

Mario L Suvà (ML)

Broad Institute, Harvard University and Massachusetts Institute of Technology, Cambridge, Massachusetts.
Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.

Ryan J Sullivan (RJ)

Department of Medicine, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts.
Massachusetts General Hospital Cancer Center, Boston, Massachusetts.

Priscilla K Brastianos (PK)

Broad Institute, Harvard University and Massachusetts Institute of Technology, Cambridge, Massachusetts.
Department of Medicine, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts.
Massachusetts General Hospital Cancer Center, Boston, Massachusetts.

Scott L Carter (SL)

Broad Institute, Harvard University and Massachusetts Institute of Technology, Cambridge, Massachusetts.
Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH